The effects of minimal increments in plasma insulin concentrations on hepatic glucose production and glucose uptake, skeletal muscle net glycogen synthesis and glycogenolysis, glycogen synthase and phosphorylase activity, glucose-6-phosphate and uridinediphosphoglucose (UDPG) concentrations were examined in 24-h and in 6-h fasted conscious rats. Insulin was infused for 120 min at rates of 1.5, 3, 6, 12, 24, and 108 pmol/kg per min in 24-h fasted rats and at rates of3, 6, 9, 12, 36, and 108 pmol/kg per min in 6-h fasted rats while endogenous insulin release was inhibited by SRIF infusion and plasma glucose was maintained at the basal level. All rats received an infusion of 13-3H Iglucose. The portion of the muscle glucose-6-phosphate (G6P) pool derived from net glycogenolysis was estimated from the ratio of specific activities of muscle UDPG and plasma glucose. Minimal increments in the circulating insulin levels, which did not stimulate glucose uptake, caused: (a) the increase in skeletal muscle glycogen synthase activity and the decrease in the rate of muscle glycogenolysis and in the G6P concentration; (b) the inhibition of hepatic glucose production. Net muscle glycogen synthesis was not stimulated despite submaximal activation of glycogen synthase, and its onset correlated with the rise in muscle G6P levels. Thus, insulin's inhibition of muscle glycogenolysis is the most sensitive insulin action on skeletal muscle and its dose-response characteristics resemble those for the inhibition of hepatic glucose production. These findings indicate that skeletal muscle glycogen synthase may play a major role in carbohydrate homeostasis even under postabsorptive (basal insulin) conditions and support the notion that insulin may exert some of its effects on the liver through an indirect or peripheral mechanism. (J. Clin. Invest.
13-3H Iglucose. The portion of the muscle glucose-6-phosphate (G6P) pool derived from net glycogenolysis was estimated from the ratio of specific activities of muscle UDPG and plasma glucose. Minimal increments in the circulating insulin levels, which did not stimulate glucose uptake, caused: (a) the increase in skeletal muscle glycogen synthase activity and the decrease in the rate of muscle glycogenolysis and in the G6P concentration; (b) the inhibition of hepatic glucose production. Net muscle glycogen synthesis was not stimulated despite submaximal activation of glycogen synthase, and its onset correlated with the rise in muscle G6P levels. Thus, insulin's inhibition of muscle glycogenolysis is the most sensitive insulin action on skeletal muscle and its dose-response characteristics resemble those for the inhibition of hepatic glucose production. These findings indicate that skeletal muscle glycogen synthase may play a major role in carbohydrate homeostasis even under postabsorptive (basal insulin) conditions and support the notion that insulin may exert some of its effects on the liver through an indirect or peripheral mechanism. (J. Clin. Invest. 1993 . 92:2963-2974.) Key words: insulin action * muscle glycogenolysis * glucose uptake * glycogen synthase * glucose-6-phosphate
Introduction
The decrease in insulin's ability to stimulate nonoxidative glucose disposal (1) (2) (3) (4) (5) and to inhibit hepatic glucose production (6, 7) is a major feature of non-insulin-dependent diabetes mellitus (NIDDM).' Glycogen synthase is believed to be the rate-limiting enzyme in the glycogen synthetic pathway (8, 9) . In NIDDM, defects have been demonstrated in both the "functional mass" of the enzyme (3) and in its activation state (2) (3) (4) . Recently, genetic (10, I1 ) and functional ( 12, 13) alterations in this enzyme have been reported in nonobese NIDDM subjects and in siblings of NIDDM individuals, suggesting the potential role of muscle glycogen synthase in the pathogenesesis of impaired glucose tolerance and diabetes. However, it is commonly believed that muscle glycogen storage does not play a significant role in the postabsorptive glucose homeostasis. Furthermore, several studies have demonstrated that the contribution of muscle glycogen storage to overall glucose fluxes is modest under physiological plasma insulin concentrations and route of carbohydrate administration (14) (15) (16) (17) (18) . In fact, following meal ingestion the transient and moderate hyperinsulinemia and hyperglycemia leads to the partial inhibition of hepatic glucose production and to the stimulation of skeletal muscle glucose uptake ( 15, 16) . The latter effect accounts for 30-50% (14-16) ofthe change in glucose metabolism and only a small portion (25-30%) ofthe glucose taken up by the skeletal muscle is stored into glycogen (15) (16) (17) .
In skeletal muscle, both plasma-derived glucose and glycogen can be phosphorylated to glucose-6-phosphate and can then enter glycolysis. In turn, glycolysis leads either to lactate formation or pyruvate oxidation in the Krebs cycle. Since the rates of net glycogen synthesis/breakdown reflect the balance ofthe glycogenic and glycogenolytic fluxes, the effect ofinsulin on this process can be mediated by either the stimulation ofthe activity of glycogen synthase as well as the inhibition of the activity ofglycogen phosphorylase. Substrate-mediated regulation of glucose uptake and of hepatic glucose production has long been recognized ( 19) . Recent evidence suggest a link between the peripheral and hepatic effects of insulin (20) (21) (22) (23) (24) (25) (26) . In fact, the inhibition of gluconeogenesis by insulin may be mediated via the intrahepatic diversion of three carbon compounds toward other pathways, namely glycolysis/oxidation and glycogen formation (26, 27) , and/or via an insulin-induced reduction in the influx of gluconeogenic substrates and energy to the liver (27, 28) .
Thus, it is important to examine the role of glycogen synthase in the regulation ofthe rates ofnet glycogenolysis in skeletal muscle and to correlate insulin action in skeletal muscle and liver under basal and physiologically hyperinsulinemic conditions. We investigated this issue by measuring the rate of hepatic glucose production and the contribution of plasma glucose to the muscle glucose-6-phosphate pool at increasing plasma insulin concentrations. Our results indicate that the muscle glycogen synthase is exquisitively sensitive to insulin's activation and, in the presence of low plasma insulin concentrations, its predominant role is to limit muscle glycogenolysis. The implication of this finding for the in vivo hepatic and peripheral sensitivity to insulin is discussed.
Methods
Animals. Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were used in all studies. Rats were housed in individual cages and subjected to a standard light (6 AM to 6 PM)-dark (6 PM to 6 AM) cycle. One week before the in vivo study, rats were anesthetized with an intraperitoneal injection of pentobarbital (50 mg/kg body wt) and indwelling catheters were inserted in the right internal jugular vein and in the left carotid artery. The venous catheter was extended to the level of the right atrium and the arterial catheter was advanced to the level of the aortic arch (29, 30) .
Euglycemic clamp study. Studies were performed in awake, unstressed, chronically catheterized rats using the euglycemic clamp technique in combination with [3-3H] glucose infusion as previously described (26, (29) (30) (31) . Rats were fasted for 6 (n = 43) or 24 (n = 42) h before the in vivo studies. These two nutritional states were selected since 24-h fast in rats is associated with marked hepatic glycogen depletion and decreased muscle glycogen concentration, while the 6-h fasted rats more closely resemble the postabsorptive state in humans, with substantial glycogen content in both liver and muscle. Basal glycogen concentrations may affect "glycogen turnover" and the response of glycogen synthase to insulin's activation. Additionally, since in 24-h fasted animals hepatic glucose production is completely due to gluconeogenesis, while in 6-h fasted animals both gluconeogenesis and glycogenolysis contribute to hepatic glucose output, the comparison ofthese two different metabolic states may add to our understanding of the relation between the effects ofinsulin on peripheral and hepatic glucose metabolism. Briefly, 5-7 d following the placement of the catheters, primed-continuous infusions of somatostatin (0.8 Mg/kg per min) and insulin (1.5-108 pmol/kg per min) or saline were administered, and a variable infusion ofa 25% glucose solution was started at time zero and periodically adjusted to clamp the plasma glucose concentration at the basal level. Somatostatin was infused in all studies in the attempt to minimize variations in the portal vein glucagon and insulin concentration in the various experimental protocols. 24-h fasted rats received an infusion ofsaline (n = 6) or insulin at either 1.5 (n = 7), 3 (n = 5), 6 (n = 6), 12 (n = 7), 24 (n = 2) or 108 (n = 9) pmol/kg per min for 2 h. 6-h fasted rats received an infusion of saline (n = 4) or insulin at either 3 (n = 4), 6 (n = 7), 9 (n = 6), 18 (n = 7), 36 (n = 5), or 108 (n = 10) pmol/kg per min for 2 h. At 90 , and 120 min during the study. The total volume of blood withdrawn was -3.0 ml/ study; to prevent volume depletion and anemia, a solution ( 1:1 vol/vol) of -4.0 ml of fresh blood (obtained by heart puncture from a littermate of the test animal) and heparinized saline ( 10 U/ml) was infused. At the end of the insulin infusion, rats were anesthetized (pentobarbital 60 mg/kg body wt, i.v.), the abdomen was quickly opened, and rectus abdominal muscle was freezeclamped in situ with aluminum tongs precooled in liquid nitrogen (32 Contribution of glycogenolysis to muscle UDPglucose in vivo. In skeletal muscle, glucose-6-phosphate and UDP glucose can derive from plasma glucose and from prestored glycogen. Under steady-state conditions, the plasma glucose specific activity and the intracellular specific activity ofUDPglucose should be equal ifall ofthe UDPglucose is from plasma, i.e., net glycogenolysis is completely suppressed. However, in the presence oflow plasma insulin concentrations, it is conceivable that a substantial portion of the glucose-6-phosphate and UDPglucose pools is derived from preexisting unlabeled glycogen, which would dilute the intracellular specific activity and decrease the ratio with the plasma specific activity. Thus, the relative net contribution of plasma glucose and glycogen to the composition of the skeletal muscle UDPg- end of the 2-h study, which represents a maximal estimate of the exchange oftritium label between glycogen and G6P pools, was negligible at the end ofthe low insulin infusion protocols (sp act ofglucosyl units in muscle glycogen = 0.056 dpm/nmol in the 24-h fasted rats and 0.087 dpm/nmol in the 6-h fasted rats); (c) finally, under hyperinsulinemic conditions, the rates of net glycogen synthesis estimated from the incorporation oftritiated glucose into muscle glycogen were similar to the rates calculated form the increment above basal in the muscle glycogen concentrations. It should also be noted that under conditions of active glycogen synthesis, when net glycogenolysis is absent, the equality of the specific activities of muscle UDPglucose and plasma glucose, though confirming the absence of net glycogenolysis, does not exclude the presence of active cycling through glycogen. In fact, under these conditions it is conceivable that the outer glucosyl units on the glycogen particles will have a specific activity similar to that of plasma glucose and their exchange with plasma-derived glucosyl units would be silent. In summary, the portion of the skeletal muscle glucose- (26) . Muscle glycogen concentration was determined after digestion with amyloglucosidase as previously described (31, 32) . The intraassay and the interassay coefficients of variation (CV) were < 10% (at 0.250 g% tissue wt) when a liver or muscle homogenate was assayed as multiple aliquots. Aliquots ofthe tissue homogenate (100 jtl) were employed to determine the amount of tritium label in glycogen. Glycogen was precipitated by washing in 10 vol ofabsolute ethanol and by incubating for 1 h at -20°C. The procedure was repeated three times and then the precipitate was collected, dried down, and dissolved in water before scintillation counting. The recovery of free [3H-3] glucose, added to test the procedure, was < 1% of the free glucose radioactivity added to the homogenate in each assay. The glycogen synthetic rate was obtained by dividing the [3H]glucose radioactivity in glycogen (dpm/g tissue) by the specific activity of [3H]UDPglucose in the same tissue sample (dpm/ nmol). The rate of net glycogen synthesis is expressed as nmol of glucose in glycogen per gm of tissue.
Glycogen synthase. Muscle glycogen synthase activity was measured by a modification (32, 34, 35) of the method of Thomas et al. (36) and is based on the measurement ofthe incorporation ofradioactivity into glycogen from UDP-[U-'4C]glucose. Tissue samples (20-30 mg) were homogenized in 2.0 ml of Tris/HCl buffer, pH 7.8, containing 10 mmol/liter EDTA, 5 mmol/liter DTT, 50 mmol/liter NaF, and 2.5 g/liter rabbit liver glycogen Type III. The homogenate was centrifuged at 2,000 gfor 15 min (at 4°C) and the supernatant used for glycogen synthase assay by measuring the incorporation of UDP-[U-'4C]glucose into glycogen at 30°C. To approximate the in vivo conditions, synthase activity was measured in the presence of physiologic 0.11 mmol/liter glucose-6-P. Total glycogen synthase D activity was measured in the presence of 7.2 mmol/liter glucose-6-P. For the kinetic analysis, the assay was conducted at final concentrations of0.003, 0.017, 0.033, 0.09, 0.33, and 1.4 mM UDPG; the data were linearized as Eadie-Hofstee plots and fit using linear regression. The Km for UDPG is the reciprocal of the slope whereas Vm,, is the y-intercept divided by the slope. To approximate the in vivo glycogenic rates, incubations are also carried out in presence of the UDPG (5-50 ,tM) and G-6-P (0.1I1 and 0.25 mM) concentrations within the physiological range for rat muscle.
Glycogen phosphorylase. Muscle glycogen phosphorylase activity was measured as previously described (35) . This assay is based on the measurement of the incorporation of '4C into glycogen from labeled glucose-I -phosphate. Glycogen phosphorylase a, the active phosphorylated enzyme, was assayed in the absence ofAMP, and phosphorylase b, the total enzyme activity, was assayed in the presence of5 mM AMP. Tissue homogenates (20-30 mg) were prepared as described above. The supernatant was used for glycogen phosphorylase assay by measuring the incorporation of ['4C]glucose-l-phosphate into glycogen at 30°C in a mixture containing 33 mM Mes, 200 mM potassium fluoride, 0.45% mercaptoethanol, 15 mM glucose-I-P (50 ACi/mmol), and 3.4 mg/ml glycogen. Phosphorylase b was assayed in the same manner except that the mixture contained 100 mM glucose-l-P (6 ,gCi/mmol), 13 .4 mg/ml glycogen, and 5 mM AMP.
Analyticalprocedures. Plasma glucose was measured by the glucose oxidase method (Glucose Analyzer II; Beckman Instruments, Inc., Palo Alto, CA) and plasma insulin by radioimmunoassay using rat and porcine insulin standards. Plasma [3H]glucose radioactivity was measured in duplicate on the supernatants ofBa(OH)2 and ZnSO4 precipitates of plasma samples after evaporation to dryness to eliminate tri- (37) . Muscle glycogen was determined as previously described (31, 32) . Muscle UDPglucose concentration and specific activity were obtained through two sequential chromatographic separations and UV detection, as previously reported (26, 33) . Plasma lactate and muscle G-6-P were measured spectrophotometrically (38, 39) . Plasma nonesterified fatty acids concentrations were determined by an enzymatic method with an automated kit according to the manufacturer's specifications (Waco Pure Chemical Industries, Osaka, Japan). Data for total body glucose uptake and suppression ofhepatic glucose production represent the mean values during the last 30 min. The hepatic glucose production was calculated as the difference between the tracer derived rate of appearance and the infusion rate of glucose. All values are presented as the mean±SEM. Comparisons between groups were made using repeated measures ANOVA where appropriate. Where F-ratios were significant, further comparisons were made using Student's t tests.
Results
General characteristics ofthe animals. The mean body wt was 303±3 g for the 24-h fasted rats and 326±5 g for the 6-h fasted animals. Both the plasma glucose (7.8±0.1 vs. 5.6±0.1 mM; P < 0.01) and insulin (204± 10 vs. 126±6 pM; P < 0.01) concentrations were significantly higher in the 6-h fasted group compared to the control group.
Insulin clamp study (Table I ; Figs. 1 and 2 ). In both groups the results obtained during the saline infusion studies and the combined somatostatin and insulin replacement infusions (1.5 and 3 pmol/kg per min, for the 24-h and 6-h fasted groups, respectively) were similar (Tables I-IV) . The plasma glucose concentration was maintained at the basal level during the insulin clamp studies (Table I) . Steady state plasma glucose concentrations during the studies were similar during the six insulin doses within the same group (Table I) . The coefficients of variation in plasma glucose and insulin levels were less than 5 and 10%, respectively, in all studies. After hyperinsulinemia the absolute plasma FFA concentration (Table I) as well as the decrement in plasma FFA concentration below the correspondent basal level were significantly reduced at the lowest dose insulin clamp study in both 24-h (+64 pM insulin) and 6-h (+86 pM insulin) fasted rats. The plasma lactate concentration was significantly reduced during the lowest dose insulin clamp study and it raised significantly above basal levels with an increase in the plasma insulin concentration of 349 pM in the 24-h fasted group and of 335 pM in the 6-h fasted group (Table  I) . Fig. 1 shows the relationships between plasma insulin concentration and hepatic glucose production (A) and tissue glucose uptake (B) in 24-h fasted rats. Fig. 2 shows the relationships between plasma insulin concentration and hepatic glucose production (A) and tissue glucose uptake (B) in 6-h fasted rats. After 24-h fast, hepatic glucose production was significantly inhibited by 22% in response to an increment of 64 pM in the plasma insulin concentration; at this plasma insulin concentration tissue glucose uptake was not stimulated. Half-maximal suppression of hepatic glucose production was achieved with an increase in the plasma insulin concentration of 188 pM, while the half-maximal stimulation of tissue glucose uptake required increasing the plasma insulin levels by 543 pM. Similarly, after 6-h fast, hepatic glucose production was significantly inhibited by 34 and 47% at plasma insulin concentrations (276 and 355 pM, respectively) at which tissue glucose uptake was not significantly stimulated. Half At the end ofthe first two low dose insulin clamp studies the muscle glycogen concentration was not significantly increased in both 6-h (44±3.9 and 47±4.6 ,tmol/g wet wt) and 24-h fasted rats (31.9±1.7 and 32.9±2.1 ,umol/g wet wt) compared to basal levels. In response to the three higher insulin infusions, muscle glycogen concentration was significantly increased in 6-h fasted (54.9±4.3, 65.3±3.9, and 84.2±4.7,gmol/g wet wt)
rats. In the 24-h fasted rats, the muscle glycogen concentration was significantly increased above basal levels at the end of the highest insulin infusion (56.8±3.9,umol/g wet wt). However, the measurement of the increment in muscle glycogen concentration may not represent a highly sensitive assay at low rates of net muscle glycogen synthesis. Thus, the rates of net muscle glycogen synthesis were assessed at the end ofthe insulin clamp studies by dividing the radioactivity accumulated in isolated muscle glycogen by the specific activity of UDPglucose in the same tissue sample (Figs. 3 A and 4 A) . During the two lowest insulin doses, there was no increment in muscle glycogen synthesis above basal level in both groups. The first significant increase in the net rates ofglycogen synthesis were measured at 525 pM insulin in the 6-h fasted rats (76.5±7.6 vs. 9.2±1.9 nmol/g wet wt per min) and at 460 pM insulin in the 24-h fasted rats (28.3±2.5 vs. 4.0±0.6 nmol/g wet wt per min).
Muscle glucose-6-phosphate concentration (Figs. 3 B and 4  B) . Skeletal muscle glucose-6-phosphate concentration was significantly decreased at low plasma insulin concentrations and increased during the highest insulin clamp studies, in both 24-h and 6-h fasted animals. Particularly, in 24-h fasted rats, the muscle glucose-6-phosphate levels were Table II ). Under postabsorptive or fasting conditions, the intracellular UDPglucose specific activity in skeletal muscle was much lower than the plasma glucose specific activity, suggesting that the majority of the skeletal muscle UDPglucose was derived from glycogen, while only a small portion, -10%, was derived from plasma glucose (Table  II) . However, with increasing insulin levels, the specific activity of muscle UDPglucose and plasma glucose progressively came together, suggesting increasing inhibition ofnet glycogenolysis. A significant inhibition of net glycogenolysis was detected in response to minimal increments in the plasma insulin concentrations (+64-+86 pM) in both 24-h and 6-h fasted rats. Figs. 4 A and S A display the high sensitivity ofthis process to insulin, with an almost complete equilibration between plasma glucose and muscle UDPglucose specific activities achieved with an increase in the plasma insulin concentrations of 300 pM. In a subgroup of rats the relation between the muscle UDPglucose and the plasma glucose specific activity was examined after 60 min of moderate hyperinsulinemia to verify the achievement ofsteady state for the two specific activities at the end ofthe in vivo studies. In 24-h fasted rats, the ratio between UDPglucose and plasma glucose specific activities was similar during the infusion of 3 pmol/kg per min insulin at 60 (Table IV) . The effect of increasing plasma insulin concentrations on glycogen phosphorylase activity is shown in Table IV . Phosphorylase a and b activities were similar at all the plasma insulin concentrations examined in both groups.
Correlations (Figs. 7 and 8 ). In both groups (24-h and 6-h fasted rats), the effect ofinsulin on skeletal muscle glycogenolysis was correlated to the effect on the hepatic glucose production and muscle glycogen synthase. (Tables I-IV) they are graphically presented in relation to the circulating insulin concentrations. The net rate of muscle glycogenolysis and the Km of the glycogen synthase (in the presence of 0.1 1 mM G6P) were significantly (P < 0.01 ) decreased in response to an increase in the plasma insulin concentration as low as 78 pM. Insulin achieved its maximal effect on these parameters with an increment in the plasma concentrations of 327 pM. min (0.23±0.04) and at 120 min (0.21±0.03). Similarly, during the infusion of 6 pmol/kg per min insulin in 6-h fasted rats, the ratio UDPglucose and plasma glucose specific activities was comparable at 60 min (0.26±0.05) and at 120 min (0.29±0.03).
The present studies were undertaken to define the dose-response relationship between insulin action on hepatic glucose production and several parameters of skeletal muscle glucose metabolism. Our results confirm the finding (6, 7, 22, 24, 32) that the hepatic glucose production is more sensitive to insulin than is the peripheral glucose uptake. However, we found that the sensitivity of skeletal muscle glycogenolysis and glycogen synthase to insulin is much higher than that of glucose uptake and similar to that of hepatic glucose production. The activation of the skeletal muscle glycogen synthase by insulin paralleled, and was highly correlated to, the insulin-mediated inhibition of net muscle glycogenolysis and this effect was submaximal at plasma insulin concentrations that did not stimulate net muscle glycogen synthesis. This observation indicates that the major role of the insulin's activation of the skeletal muscle glycogen synthase at low physiological plasma insulin levels is to limit net glycogenolysis and that this is an exquisitely sensitive insulin action.
The relationship between circulating plasma insulin concentration and skeletal muscle glycogenolysis has not been previously examined. However, the effect of euglycemic insulin infusions on skeletal muscle glycogen synthase has been extensively examined in both humans (2, 4, 8, 12, 13, 40, 41 ) Figs. 3 A and 4 A) and confirmed by the lack of increase in the muscle glycogen concentrations. This observation is consistent with the finding in humans of a lack of insulin-mediated stimulation of the nonoxidative pathways of glucose disposal up to -200 pM (41, 47) . However, in response to these modest increments in the plasma insulin concentrations the skeletal muscle glycogen synthase activity was significantly stimulated and the intracellular specific activity ofthe exose-phosphates was promptly and progressively equilibrating with the extracellular glucose specific activity, thus suggesting the inhibition ofnet muscle glycogenolysis by insulin.
Muscle glucose-6-phosphate levels were decreased in response to an increment in the plasma insulin concentration of -100 pM. This decline appears to be the consequence of the unbalance between the insulin's effects on muscle glycogenolysis and perhaps glycolysis, and the lack ofsignificant activation of glucose transport/phosphorylation. Furthermore, the decrease in both glucose-6-phosphate and UDP-glucose concentrations may contribute to the lack of net glycogen deposition despite significant activation of glycogen synthase at these low insulin concentrations. Together our results suggest that insulin's stimulation of glucose uptake and subsequent rise in the skeletal muscle glucose-6-phosphate concentration toward basal or suprabasal levels are necessary for the onset of net glycogen synthesis in skeletal muscle.
The concentration ofmuscle glucose-6-phosphate may also help to elucidate an additional discrepancy between the effect ofinsulin on muscle glycogen synthase and net glycogen synthesis. The insulin's activation of muscle glycogen synthase was almost maximal at -500 pM plasma concentration in both 6-and 24-h fasted animals. However, the net rate ofmuscle glycogen synthesis was progressively and markedly increased by further elevations in the plasma insulin concentration from -500 to -2500 pM. The muscle glucose-6-phosphate concentration returned to approximately the basal levels at -500 pM and progressively increased at higher plasma insulin concentrations. It is tempting to speculate that, in the presence ofa fully activated glycogen synthase, the increase in the muscle glucose-6-phosphate concentration modulates the in vivo rate of glycogenesis. Consistent with this hypothesis, a > 40% decrease in the Km ofmuscle glycogen synthase was demonstrated in vitro by increasing the G-6-P concentration from 0.1 1 (53, 54 ). An effect of insulin on the CNS may also affect the hepatic glucose output through changes in the firing of hepatic sympathetic and parasympathetic innervation (55) . Finally, the hormone may regulate the supply of energy and key substrates to the liver (25, 28) . Such ysis was highly correlated with the hormone's activation ofglycogen synthase, there was no detectable effect of insulin on glycogen phosphorylase. This finding is consistent with previous in vivo studies (35, 48) and appears to indicate that the activation ofglycogen synthase plays the major role in insulin's inhibition of net muscle glycogenolysis. However, these results should be cautiously interpreted, since the in vitro assay of glycogen phosphorylase may not reflect its in vivo activity (49) and an additional effect of insulin on the in vivo activity of glycogen phosphorylase cannot be ruled out. In the present study the insulin-dependent inhibition of skeletal muscle glycogenolysis was highly correlated with the insulin's inhibition of hepatic glucose production. Furthermore, the EC50 for the effects of insulin on hepatic glucose production and skeletal muscle glycogenolysis were similar. The reproducibility of these findings under different metabolic and nutritional conditions strengthens this conclusion. Thus, some of the in vivo peripheral and hepatic effects of the hormone follow similar dose-response characteristics. Recent evidence has indicated that the ability of insulin to inhibit hepatic glucose production in vivo is partially due to its extrahepatic effects (20) (21) (22) (23) (24) . Particularly, several studies have shown that A X 100- an effect may be particularly important, in combination with direct hormonal signals, for the inhibition ofhepatic gluconeogenesis. Under postabsorptive conditions a large portion oflactate and alanine carbons are derived from skeletal muscle glycogenolysis (25) , thus, the exquisite sensitivity of this process to insulin may suggest its role in decreasing the supply of gluconeogenic precursors to the liver. However, it is important to point out that the correlation between the effects of insulin on skeletal muscle glycogenolysis and hepatic glucose production was observed in both 24-h fasted rats, which are depleted of hepatic glycogen and largely depend on gluconeogenesis for sustaining their hepatic glucose output, and in 6-h fasted animals, which equally rely on hepatic gluconeogenesis and glycogenolysis. Therefore, the proposed peripheral signal to the liver has to involve a concomitant effect on hepatic gluconeogenesis and glycogenolysis. It may be tempting to speculate that one or more ofthe substrates that are affected by the peripheral effects of insulin may also contribute to the modulation of hepatic glycogen metabolism (56) . This study may also be relevant to the interpretation of commonly used whole body tracer methodology. In fact, several tracer approaches to the study ofglucose and lactate turnover and oxidation assume a complete equilibrium between intracellular and extracellular specific activities (32, 57, 58) . For skeletal muscle, the source of intracellular dilution of specific activity at the level of the exose-phosphate pool is the preexisting unlabeled glycogen. With an elegant experimental approach in humans, Butler and co-workers (58) suggested that high physiological to pharmacological insulin concentrations were required for the complete equilibration of the intracellular specific activity of glucose-6-phosphate with the plasma glucose specific activity. The present observation provides experimental support for the notion that under basal insulin conditions a large portion ofthe intracellular exose-phosphates is derived from glycogen rather than plasma glucose (58) . However, it indicates that, at least in conscious rats, the equilibration ofthe extracellular and intracellular specific activity is very sensitive to insulin, since it occurs in response to a modest physiological increment in the plasma insulin concentrations.
In summary, the present data demonstrate that insulin suppresses in vivo hepatic glucose production and skeletal muscle glycogenolysis with virtually identical sensitivity. The insulinmediated suppression of skeletal muscle glycogenolysis is highly correlated to its activation ofglycogen synthase and contributes to the drop in the skeletal muscle glucose-6-phosphate concentration. The sensitivity to insulin ofboth Rd and muscle glycogen synthesis is much lower than that ofmuscle glycogenolysis. Since net muscle glycogen synthesis does not initiate despite submaximal insulin's activation of glycogen synthase, it is suggested that at low plasma insulin concentration glycogen synthesis in skeletal muscle is limited by glucose transport or phosphorylation.
